In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Janux Therapeutics Inc’s stock clocked out at $13.72, down -2.83% from its previous closing price of $14.12. In other words, the price has decreased by -$2.83 from its previous closing price. On the day, 1.45 million shares were traded. JANX stock price reached its highest trading level at $14.2 during the session, while it also had its lowest trading level at $13.55.
Ratios:
To gain a deeper understanding of JANX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 35.86 and its Current Ratio is at 35.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On September 17, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $47.
On September 10, 2025, Truist started tracking the stock assigning a Buy rating and target price of $100.Truist initiated its Buy rating on September 10, 2025, with a $100 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’26 when Meyer Andrew Hollman sold 1,879 shares for $13.73 per share. The transaction valued at 25,799 led to the insider holds 83,095 shares of the business.
DiRaimondo Thomas sold 2,505 shares of JANX for $34,394 on Jan 02 ’26. The Chief Scientific Officer now owns 124,425 shares after completing the transaction at $13.73 per share. On Jan 02 ’26, another insider, Campbell David Alan, who serves as the President and CEO of the company, sold 8,072 shares for $13.73 each. As a result, the insider received 110,829 and left with 284,982 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 825227968 and an Enterprise Value of -141105088. For the stock, the TTM Price-to-Sale (P/S) ratio is 82.52 while its Price-to-Book (P/B) ratio in mrq is 0.84. Its current Enterprise Value per Revenue stands at -14.111 whereas that against EBITDA is 0.992.
Stock Price History:
The Beta on a monthly basis for JANX is 2.87, which has changed by -0.65324163 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $47.58, while it has fallen to a 52-week low of $13.26. The 50-Day Moving Average of the stock is -32.58%, while the 200-Day Moving Average is calculated to be -43.26%.
Shares Statistics:
It appears that JANX traded 1.93M shares on average per day over the past three months and 1500170 shares per day over the past ten days. A total of 60.12M shares are outstanding, with a floating share count of 53.48M. Insiders hold about 11.09% of the company’s shares, while institutions hold 106.98% stake in the company. Shares short for JANX as of 1767139200 were 9239650 with a Short Ratio of 4.79, compared to 1764288000 on 7606181. Therefore, it implies a Short% of Shares Outstanding of 9239650 and a Short% of Float of 22.06.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Janux Therapeutics Inc (JANX).The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.56 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$1.28 and -$2.56 for the fiscal current year, implying an average EPS of -$1.97. EPS for the following year is -$2.97, with 13.0 analysts recommending between -$2.38 and -$4.6.
Revenue Estimates
A total of 15 analysts have provided revenue estimates for JANX’s current fiscal year. The highest revenue estimate was $11M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $10.07M. In the same quarter a year ago, actual revenue was $10.59M
